Dr Andy Richards CBE
Appointed Chairman, Advisory Panel.
Andy is Chairman of Congenica, Arecor, and Abcodia, and is a director of Silence Therapeutics plc, Ieso Digital Health, Sensiia, and Cancer Research Technology (commercial arm of CR-UK). He is Chair of the Babraham Research Campus and was until recently a non-executive director of Cambridge University Hospitals Trust.
His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience. Since 1999 he has founded, invested in and helped to scale innovative UK based biotechnology and healthcare companies, with more than 25 ventures over the last 16 years. These include companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels, and was awarded a CBE in 2015 for services to life-science investment.
Prof Chris Frampton
Chris is a co-founder and operates as the company’s Chief Scientific Advisor. A world-renowned X-Ray Crystallographer, Chris holds both academic and commercial roles and featured in Medicine Maker’s ‘Top 100 Most Influential Medicine Maker Power List” in April 2015. Chris was also a Cofounder, Director and Chief Scientific Officer of Pharmorphix Ltd (July 2003), acquired by SAFC Pharma in August 2006. Previously, Chris was Director of Strategic Marketing at Bruker AXS where he was responsible for new technology in the bio-market. More recently, Chris has taken up a Chair in Structural Chemistry and Crystal Engineering within the Wolfson Centre for Materials Processing at Brunel University and holds the post of Research Associate of Girton College, University of Cambridge. Chris is also founder and CEO of RBar3, a crystallographic consultancy.
Dr Jeffery Lindeman
Dr Lindeman is an esteemed Intellectual Property consultant and patent attourney at J. A. Lindeman LLC. A renowned thought leader in the field, Dr Lindeman is a world-leading expert in legal issues relating to pharmaceutical solid form intellectual property.
Dr Stephen Cash
Dr Cash started his career with ICI covering sales, marketing, logistics, strategic planning, and new business development. In 1992, Dr Cash led the first ICI business unit MBO, establishing Cleveland Chemicals Ltd, later sold to the Yule Catto group. Since then he has worked in new business development and technology scouting for Thomas Swan & Co Ltd, establishing world leading technologies in areas such as carbon nanotube and carbon nanofibre manufacture in addition to a number of start-up companies (Screen Technology plc, was floated on the AIM market). Dr Cash remains a non-executive director of four start-ups created during this time and sits on the advisory board of the Materials Science Department at the University of Cambridge.
Prof Derek Mann
Nuformix has been working with Derek and his team to further validate NFX002, the Nuformix fibrosis programme. Derek will continue to advise the Nuformix team in pre-clinical fibrosis research.
He is Director of the Newcastle Fibrosis Research Group (NFRG), which is focussed on developing translational solutions to tissue remodelling and scar formation in the liver, lung, kidneys, heart and skin. Derek’s research group is primarily interested in understanding the molecular basis for liver fibrosis (scarring) and primary liver cancer. Recent discoveries include mechanisms of transgenerational epigenetic inheritance affecting fibrosis and a role for inflammatory neutrophils in hepatocellular carcinoma.
At the NFRG he has developed a number of collaborative strategic alliances with major pharmaceutical companies including GSK and Abbvie, which are aimed at translation of the NFRG research to the design of fibrosis biomarkers and new therapeutics. He is also the Dean of Research and Innovation in the Faculty of Medical Sciences at Newcastle University.
Dr Paul Goldsmith
Paul joins the Advisory Panel.
He is a commercial medic with experience founding and building both drug and digital health companies and is now co-leading the development of Closed Loop Medicine Ltd. He is a Consultant Neurologist, trained in Cambridge, Oxford, London and Newcastle. His insights into the translational clinical-commercial interface will be invaluable to Nuformix.
Nuformix is able to draw upon a broad pool of recognised world leaders covering aspects from disease expertise and clinical strategy through to drug solid form and pharmaceutical product development. The Advisory Board is comprised of a highly complimentary individuals, active in both industry and academia and who continue to research, patent and publish. Their collective expertise has enabled Nuformix to build focused portfolios around specific indications and disease fields by providing a complete view from early cocrystal target identification to eventual clinical validation.